Last reviewed · How we verify
Nallpen In Plastic Container (NAFCILLIN)
Nafcillin is a penicillin-class antibacterial medication originally developed by Wyeth Ayerst. It is a small molecule modality that has been FDA-approved since 1965 for various bacterial infections, including those caused by Staphylococcus aureus. Nafcillin is off-patent and has multiple generic manufacturers. It has a short half-life of 0.7 hours and limited bioavailability of 30%. As a result, it is typically administered intravenously to treat a range of infections.
At a glance
| Generic name | NAFCILLIN |
|---|---|
| Sponsor | Pfizer |
| Drug class | Penicillin-class Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
- Acute bacterial sinusitis
- Infection due to Staphylococcus aureus
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Osteomyelitis due to Staphylococcus aureus
- Sepsis due to Staphylococcus aureus
- Staphylococcal Prosthetic Heart Valve Endocarditis
- Staphylococcal endocarditis
- Staphylococcal infectious disease
- Staphylococcal meningitis
- Staphylococcal pneumonia
- Staphylococcus Aureus Joint Infection
Common side effects
- Allergic reactions
- Urticaria
- Pruritus
- Angioedema
- Laryngospasm
- Bronchospasm
- Hypotension
- Vascular collapse
- Death
- Nausea
- Vomiting
- Diarrhea
Drug interactions
- CYP3A4 Substrates
- levonorgestrel
- norgestimate
- warfarin
Key clinical trials
- Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)? (PHASE1)
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
- Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia (PHASE2)
- Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections (PHASE4)
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nallpen In Plastic Container CI brief — competitive landscape report
- Nallpen In Plastic Container updates RSS · CI watch RSS
- Pfizer portfolio CI